Dr. Dongyuan Zhu 朱栋元
Chief Physician
Department of Rare Tumors, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, drug therapy, and ultrasound-guided minimally invasive treatment for rare tumors, including bone and soft tissue sarcomas, melanoma, genitourinary cancers, and head and neck tumors.
Dr. Zhu is Chief Physician and Director of the Rare Tumor Department at Shandong Cancer Hospital. Holding a PhD in Oncology, Dr. Zhu is a master’s supervisor and was a visiting scholar at the University of Texas Dallas. Dr. Zhu leads the multidisciplinary team for bone, soft tissue, and melanoma tumors.
Professional roles
- Chair, Rare Tumor Branch, Shandong Rare Disease Association
- Vice Chair, Chemotherapy Branch, Shandong Anti-Cancer Association
- Vice Chair, Molecular Targeted Therapy Branch, Shandong Research Hospital Association
- Member, National Cancer Quality Control Center Laryngeal Cancer Expert Committee
Name order: in Chinese the family name comes first (Zhu Dongyuan). Papers usually list the name as Dongyuan Zhu or Zhu D.
Selected publications
27 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial. PubMed 42338591
- Clin Cancer Res, 2026 (senior author): First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial. PubMed 41128656
- Cancer Immunol Res, 2025 (senior author): Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial. PubMed 40874581
- Medicine (Baltimore), 2024 (senior author): Two cases of inflammatory myofibroblastic tumor treated with targeted drugs: A case report. PubMed 38787978
- Laryngoscope Investig Otolaryngol, 2023 (senior author): Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single-center experience of eight patients. PubMed 37090874
- Sci Rep, 2023 (senior author): Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study. PubMed 36854710
- Front Genet, 2022 (senior author): Case Report: Primary Pleural Angiosarcoma in a Patient With Klippel-Trenaunay Syndrome. PubMed 35154272
- Tohoku J Exp Med, 2020 (senior author): Membrane Location of Syntaxin-Binding Protein 1 Is Correlated with Poor Prognosis of Lung Adenocarcinoma. PubMed 32321873
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion